The associated overexpression of MCT1 is an indicator of dependency of statin treated tumours on this transporter for efficient metabolism as a compensatory survival mechanism, suggesting that blocking this compensatory pathway could be of therapeutic benefit. Here, SLC16A1 is linked to neoplasm.